CRISPR Therapeutics AG
CRISPR Therapeutics is pioneering a new era of medicines by rapidly translating revolutionary gene editing technology into therapies. The company is focused on developing transformative gene-based medicines for serious diseases, with a diverse portfolio across disease areas including hemoglobinopathies, oncology, diabetes, and cardiovascular disease. They have achieved the first-ever approved CRISPR-based therapy and are at the forefront of scientific innovation in gene editing.
Industries
Nr. of Employees
large (251-1000)
CRISPR Therapeutics AG
105 West First Street, South Boston, MA 02127
Patents
Materials and methods for treatment of autosomal dominant retinitis pigmentosa
US-12247201-B2
View Details
Materials and methods for treatment of autosomal dominant retinitis pigmentosa
US-12247201-B2
View DetailsProducts
Gene-edited hematopoietic stem cell therapy for hemoglobinopathies
A CRISPR/Cas-based gene-edited hematopoietic stem cell therapy developed to treat severe sickle cell disease and transfusion-dependent β-thalassemia; reported as authorized for use in some jurisdictions for eligible patients.
Gene-edited hematopoietic stem cell therapy for hemoglobinopathies
A CRISPR/Cas-based gene-edited hematopoietic stem cell therapy developed to treat severe sickle cell disease and transfusion-dependent β-thalassemia; reported as authorized for use in some jurisdictions for eligible patients.
Services
Strategic alliances with external biopharma and research organizations to co-develop nucleic acid- and cell-based therapeutic programs.
Programs to engage patient communities, support advocacy groups, and provide information on clinical research and expanded access to investigational medicines.
Strategic alliances with external biopharma and research organizations to co-develop nucleic acid- and cell-based therapeutic programs.
Programs to engage patient communities, support advocacy groups, and provide information on clinical research and expanded access to investigational medicines.
Expertise Areas
- Gene editing therapeutics
- Ex vivo hematopoietic stem cell therapies
- In vivo genome editing
- Cell therapy development (oncology and autoimmune)
Key Technologies
- CRISPR/Cas gene editing
- Ex vivo HSC editing
- In vivo genome editing
- Cell therapy platforms
News & Updates
CASGEVY™ (exagamglogene autotemcel), a CRISPR/Cas9 gene-edited therapy, is approved in some countries for certain eligible patients with sickle cell disease or transfusion-dependent beta thalassemia.
CASGEVY™ (exagamglogene autotemcel), a CRISPR/Cas9 gene-edited therapy, is approved in some countries for certain eligible patients with sickle cell disease or transfusion-dependent beta thalassemia.